MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (“MedX”) (TSX-V:MDX) announces that it has partnered
with SANITAS, a specialist in healthcare and well-being services in
Spain, to conduct a skin cancer screening initiative. According to
recent studies, Spain, with its warm and sunny climate has experienced a
50% increase in skin cancer rates over the last decade. It is the most
common form of cancer in women between the age of 25 and 29, followed by
breast cancer, and the most common in men between the age of 30 and 35,
ahead of lung and colon cancer.
MedX, with its Spanish distributor (OncoTech), has partnered with
SANITAS, who will target twelve of SANITAS’s multi-national company
customers, with up to 3,000 patient scans to be taken using MedX’s
DermSecure™, to assess the benefits of such an initiative to SANITAS,
its clients and the Spanish healthcare system. Upon completion, SANITAS
will consider a significant expansion of this program. Dr. Miguel Marine
Blanco, Director of Strategic Alliances for SANITAS commented, “With the
increase in skin cancer rates in Spain we felt being able to offer our
members skin cancer screening with the best screening technology
available would be well received by our members.”
Sanitas offers its clients products and services adapted to people’s
real needs at each stage of their lives through an integral healthcare
model that includes: medical insurance, hospitals and multi-speciality
centres, well-being centres, dental clinics, other health services and
services for the care of the elderly. Sanitas forms part of Bupa, a
leading international healthcare company, which serves over 15.7 million
insurance policy holders, 15 million patients and 23,000 elderly people.
Mr. Frank Melendez, OncoTech’s President stated, “It is an honour to
work with SANITAS and their multi-national customers. They truly wish to
deliver the best possible care to their members which speaks to their
success. We are looking forward to the results of this pilot and to
further expand this program in the future.”
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device
and software company focused on skin cancer with its DermSecure™
telemedicine platform, utilizing its SIAscopy technology. SIAscopy is
also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which
MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™,
SIMSYS™, and MoleMate™ include hand-held devices that use patented
technology utilizing light and its remittance to view up to 2 mm beneath
suspicious moles and lesions in a pain free, non-invasive manner, with
its software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use
in Canada, the US, Australia, New Zealand, the European Union and
Turkey. MedX also designs, manufactures and distributes quality
photobiomodulation therapeutic and dental lasers to provide drug-free
and non-invasive treatment of tissue damage and pain. www.medxhealth.com
About SANITAS
Sanitas is a specialist in healthcare and well-being services in Spain.
It offers its clients products and services adapted to people’s real
needs at each stage of their lives through an integral healthcare model
that includes: medical insurance, hospitals and multi-speciality
centres, well-being centres, dental clinics, other health services and
services for the care of the elderly.
It has 10,859 employees; it has a medical team made up of over 40,000
specialists and 1,200 associated medical centres, in addition to its own
service, formed by 4 hospitals, 20 multi-speciality medical centres, 16
well-being centres, 180 dental clinics, 47 homes for the elderly, 17 of
them with day centre services and 5 independent day centres.
Sanitas forms part of Bupa, a leading international healthcare company,
which serves over 15.7 million insurance policy holders, 15 million
patients and 23,000 elderly people.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which
reflect the Company’s current expectations regarding future events. The
forward-looking statements involve risks and uncertainties.
Contacts
Scott Spearn, President and CEO
MedX Health Corp
905-670-4428
ext 229
